GEN Exclusives

More »

GEN News Highlights

More »
Nov 11, 2010

Agenta Wins $1.1M SBIR Grant to Develop Regenerative Membrane for Oral Surgery

  • Regenerative therapies firm Agenta Biotechnologies received a $1.1 million grant from the NIH and National Institute of Dental and Craniofacial Research to further develop a biologically activated membrane designed to help promote soft tissue healing associated with oral surgery. The award is the second SBIR grant to have been received by Agenta.

    The firm is exploiting its Customized Therapeutic Proteoglycan Delivery (CTPD) platform to develop proteoglycan-based therapies for tissue regeneration and healing. Agenta claims the technologies allows the precise control and manipulation of proteoglycan DNA sequences for development of products with potential applications in a wide range of regenerative uses including healing bone, cartilage, skin, and spinal discs and as coatings for vascular stents and implants.

    The company is currently working in partnership with Boneta to develop therapeutics for enhanced bone healing in the skull and for the growth of new bone in the jaw and around teeth. Previous SBIR grant funding led to completion of certain preclinical studies, which showed postive results. Agenta says the firms aim to meet with FDA to discuss the prospect of starting clinical trials.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?